NCT05752136View on ClinicalTrials.gov

Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

December 31, 2028

Conditions
Rectal Cancer
Interventions
BIOLOGICAL

Envafolimab

This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).

Trial Locations (1)

310016

RECRUITING

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Sir Run Run Shaw Hospital

OTHER